It's a very new and early stage company. There aren't indicative revenues.
The main game for MDR right now is signups, pharma deals, rolling-out GP Link and securing market share/"preferred" status in the industry.
If they can expedite these agendas then they may not need to raise capital for quite some time, although I wouldn't be upset if they had to raise a little to help achieve scale.
Ann: Major Biopharmaceutical Signs to Patient Engagement Program-MDR.AX, page-22
-
- There are more pages in this discussion • 22 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MDR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
30.0¢ |
Change
0.010(3.45%) |
Mkt cap ! $215.0M | |||
| Open | High | Low | Value | Volume |
| 29.0¢ | 30.0¢ | 27.5¢ | $254.8K | 889.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 39326 | 30.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.5¢ | 2917 | 1 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| MDR (ASX) Chart |
